Literature DB >> 3697717

Increase in hypothalamic cholecystokinin following acute and chronic morphine.

P L Faris, M C Beinfeld, A C Scallet, J N Johannessen, J W Olney.   

Abstract

Recent evidence supports an antagonistic interaction between cholecystokinin (CCK) and opiate peptides. The present study determined the effects of various levels of morphine treatment on hypothalamic levels of CCK as determined by radioimmunoassay. Acute treatment with morphine sulfate (10 mg/kg) or implantation of one morphine pellet (75 mg free base) increased levels of CCK in whole hypothalamus. Increased exposure to morphine by either chronic injections or implantation of two pellets did not result in a further change in whole hypothalamic CCK levels. In samples dissected into hypothalamic subregions, the effect of morphine on CCK levels was localized to medial but not lateral or posterior regions. These experiments extend earlier in vitro findings and suggest that some of the physiological and behavioral effects of opiate peptides may result from modulation of endogenous CCK.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3697717     DOI: 10.1016/0006-8993(86)91629-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  1 in total

1.  CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat.

Authors:  X J Xu; Z Wiesenfeld-Hallin; J Hughes; D C Horwell; T Hökfelt
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.